Scholar Rock’s (SRRK) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Scholar Rock (NASDAQ:SRRK) in a report issued on Tuesday morning,Benzinga reports. They currently have a $58.00 price target on the stock.

Several other analysts have also issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Friday, July 17th. Barclays upped their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Canaccord Genuity Group began coverage on Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 target price on the stock. Finally, HC Wainwright boosted their price target on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $56.00.

Scholar Rock Stock Up 2.4%

SRRK opened at $49.48 on Tuesday. The business has a 50 day moving average of $50.05 and a 200-day moving average of $47.47. The stock has a market capitalization of $5.93 billion, a price-to-earnings ratio of -13.78 and a beta of 0.67. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. Scholar Rock has a 1-year low of $27.07 and a 1-year high of $58.49.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period last year, the company earned ($0.67) EPS. As a group, sell-side analysts anticipate that Scholar Rock will post -3.23 earnings per share for the current year.

Insider Activity

In other Scholar Rock news, Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the sale, the director owned 59,511 shares of the company’s stock, valued at $3,205,857.57. The trade was a 4.10% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of Scholar Rock stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the sale, the director owned 34,301 shares in the company, valued at approximately $1,848,137.88. This trade represents a 13.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 17,149 shares of company stock valued at $923,108. 10.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently modified their holdings of the stock. IFP Advisors Inc raised its holdings in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after buying an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Scholar Rock in the 4th quarter valued at $30,000. Summit Securities Group LLC acquired a new stake in Scholar Rock in the 4th quarter valued at $31,000. EverSource Wealth Advisors LLC grew its position in Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares during the period. Finally, Hilton Head Capital Partners LLC bought a new stake in Scholar Rock in the fourth quarter valued at $44,000. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).